SCHEMBL7795186

SCHEMBL7795186

C1CCC(NC2CCCCC2)CC1.Cc1cc(OCCCC(=O)O)c(C)c(C)c1S(=O)(=O)NC(=N)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
BRD4 O60885 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 2/20 0.36
TSHR P16473 1/20 0.36
LMNA P02545 1/20 0.36
FABP3 P05413 3/20 0.35
FABP4 P15090 3/20 0.35
AVPR1A P37288 1/20 0.35
HTT P42858 1/20 0.35
TP53 P04637 1/20 0.34
GAA P10253 1/20 0.34
AVPR1B P47901 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7795595 0.81 L3MBTL1 (0.39) ALDH1A1HPGDGAA
SCHEMBL7795476 0.75 AR (0.35) ALDH1A1KDM4ESMN1; SMN2TSHRLMNA
SCHEMBL7797943 0.68 PSEN1 (0.35)
SCHEMBL7799028 0.68 MAPT (0.37) BRD4SMN1; SMN2LMNA
SCHEMBL3454975 0.63 MEN1 (0.74) MEN1KMT2ABRD4ALDH1A1SMN1; SMN2
SCHEMBL3193052 0.62 KMT2A (0.51) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2
Velaresol SCHEMBL11157225 0.62 CNR2 (0.45) MEN1KMT2APTGDR2ALDH1A1KDM4E
SCHEMBL27894060 0.62 EPHX1 (0.53) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2
Adipic Acid SCHEMBL27316347 0.60 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2HPGDTSHRLMNA
SCHEMBL8752667 0.60 TSHR (0.68) MEN1KMT2AHPGDTSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010012901-A1 Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2001-08-09 US disclosed
US-6225480-B1 FOR SYNTHESIS OF ORGANIC COMPOUNDS CONTAINING--NH--GROUPS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-05-01 US disclosed
EP-0948480-A1 SULPHONYL COMPOUNDS FOR USE AS LINKERS IN SOLID PHASE AND COMBINATORIAL SYNTHESIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-13 EP disclosed
WO-1998029386-A1 SULPHONYL COMPOUNDS FOR USE AS LINKERS IN SOLID PHASE AND COMBINATORIAL SYNTHESIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010012901-A1 Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis H1-0, H1-2, ASH2L MEN1 1879/4885KMT2A 173/4885BRD4 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.